Innovative Therapeutics in Oncology and Neuroscience
KarXT - Anchor Asset to Expand into Neuroscience
Late-stage
Recognized Need for More Effective Treatment
for Patients with Schizophrenia
>8 million 1 people in China living with schizophrenia
Half of the patients are not seeking professional care²
Profound burden of disease despite available therapies
•
•
Lack of novel MOA
Poor negative symptom control
Often unacceptable side effects, including weight gain,
somnolence, tardive dyskinesia, extrapyramidal
syndrome (EPS), neuroleptic malignant syndrome
Potential to Change the Standard of Care
in Schizophrenia
✓ Novel MOA
✓ Early and sustained reduction of positive and negative
symptoms of schizophrenia
Generally well-tolerated, with manageable safety and
tolerability profile
✓ Not associated with common AEs of current
antipsychotic medications
✓ Considered use as mono- and combination therapies
Innovative Treatment Option to Address Significant Unmet Medical Needs in China to Treat Patients
with Serious Psychiatric Conditions
45
Sources: Karuna corporate presentation, May 2023. Zai Lab analysis.
Note: (1) China has estimated more than 8 million schizophrenia patients (prevalence rate is 0.6% -0.655%). Prevalence of mental disorders in China: a cross-sectional epidemiological study. The Lancet Psychiatry, 2019; (2) According to the data from the
Ministry of Civil Affairs of the PRC, there are 6.2 million registered mental disorder cases in the national severe mental illness management system in 2020. An expert from Guangdong Provincial Mental Health Center estimated that -70% of registered
mental disorder cases are schizophrenia patients in 2020.
Clinical Data -
NeuroscienceView entire presentation